What Is SLU-PP-332?

SLU-PP-332 is a synthetic, non-steroidal small molecule that belongs to the emerging class of compounds known as exercise mimetics—substances designed to replicate the cellular and metabolic effects of physical exercise without requiring actual physical activity. Developed by a research team led by Dr. Thomas P. Burris at the Center for Clinical Pharmacology at Washington University School of Medicine and St. Louis College of Pharmacy, the compound was first described in a landmark 2023 paper published in ACS Chemical Biology that has since been cited more than 36 times across top-tier journals including Nature, Circulation, and Pharmacological Reviews (Billon et al., 2023).

The name “SLU-PP-332” itself provides a clue to its origins. “SLU” stands for Saint Louis University, where the early precursor work was conducted before the research group moved to Washington University. The “PP” designation references the laboratory naming convention, and “332” identifies the specific compound within the chemical series. Dr. Burris has since relocated to the University of Florida Genetics Institute, where development of next-generation ERR agonists continues.

SLU-PP-332 Is Not Actually a Peptide

Despite its widespread marketing as a “peptide” across research chemical suppliers and online forums, SLU-PP-332 is technically not a peptide. Peptides are defined as short chains of amino acids linked by peptide bonds—compounds like BPC-157, TB-500, and KPV fall into this category. SLU-PP-332, by contrast, is a small organic molecule with a distinct chemical scaffold that does not contain amino acid sequences. It is classified as a small molecule ligand that binds to nuclear receptors, placing it in a pharmacological category more comparable to pharmaceutical drugs like tamoxifen or rosiglitazone than to research peptides. The term “SLU-PP-332 peptide” persists largely because research chemical suppliers categorize it alongside peptides for commercial convenience, and the broader research community has adopted the terminology colloquially.

Chemical Profile and Classification

From a pharmacological standpoint, SLU-PP-332 is classified as a pan-agonist of the estrogen-related receptor family. It targets all three ERR subtypes—ERRα, ERRβ, and ERRγ—but demonstrates the highest binding potency for ERRα. The compound possesses sufficient pharmacokinetic properties for in vivo use, meaning it can be administered to living organisms and reach its target tissues at effective concentrations. In published mouse studies, it was administered via intraperitoneal injection at 25 mg/kg twice daily and demonstrated measurable biological activity within two hours of the first dose, as evidenced by an immediate shift in respiratory exchange ratio toward fat oxidation (Billon et al., 2024).

How Does SLU-PP-332 Work? The ERR Agonist Mechanism of Action

Understanding how SLU-PP-332 produces its exercise-mimicking effects requires a deeper look at the estrogen-related receptors it targets and the downstream biological cascades those receptors control. The mechanism is elegant, multi-layered, and fundamentally different from how stimulants, fat burners, or anabolic compounds work.

What Are Estrogen-Related Receptors (ERRs)?

Estrogen-related receptors are a family of three orphan nuclear receptors—ERRα, ERRβ, and ERRγ—that were originally identified because of their structural similarity to estrogen receptors. However, despite the potentially confusing name, ERRs do not bind estrogen and have no direct role in estrogen signaling or reproductive biology. They are called “orphan” receptors because, until recently, no natural ligand (binding molecule) had been definitively identified for them. Instead, they are constitutively active transcription factors that regulate the expression of genes involved in cellular energy metabolism.

Each ERR subtype plays a distinct but overlapping role in energy homeostasis. ERRα is the most extensively studied and is highly expressed in metabolically demanding tissues including skeletal muscle, heart, kidney, and brown adipose tissue. It serves as a master regulator of mitochondrial biogenesis, fatty acid oxidation, and oxidative phosphorylation—essentially controlling the genetic programs that determine how efficiently your cells produce energy from nutrients. ERRβ is less well characterized but plays important roles in placental development and inner-ear function. ERRγ is highly expressed in the heart and brain and shares substantial functional redundancy with ERRα in regulating cardiac metabolism and muscle contraction (Burris et al., Pharmacol. Rev., 2023).

The Three-Stage Activation Cascade

When SLU-PP-332 enters a cell and binds to ERRα, it triggers a precise sequence of molecular events that can be understood as a three-stage activation cascade. In the first stage, receptor activation, SLU-PP-332 binds to the ligand-binding domain of ERRα, inducing a conformational change that enhances the receptor’s ability to recruit transcriptional coactivators, particularly PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha). PGC-1α is frequently described as the “master regulator” of mitochondrial biogenesis, and its recruitment is the critical event that bridges receptor activation to metabolic reprogramming.

The second stage involves transcriptional reprogramming. The ERRα-PGC-1α complex binds to estrogen-related receptor response elements (ERREs) in the promoter regions of hundreds of target genes. RNA sequencing studies from the Circulation heart failure paper identified over 1,100 differentially expressed genes in response to ERR agonist treatment, with upregulated genes enriched in fatty acid metabolism, oxidative phosphorylation, and cardiac muscle contraction pathways (Xu et al., 2024). Simultaneously, cell cycle and developmental genes were downregulated, suggesting that ERR activation redirects cellular resources away from growth and proliferation toward metabolic efficiency.

The third stage produces the functional metabolic output. New mitochondria are assembled within muscle fibers (mitochondrial biogenesis), existing mitochondria become more efficient at burning fatty acids (enhanced β-oxidation), and muscle cells shift from glycolytic (fast-twitch, sugar-burning) fibers toward oxidative (slow-twitch, fat-burning) fibers. The net result is a cell that looks and behaves as though it has been subjected to weeks of endurance training—despite receiving a chemical signal rather than a mechanical one.

ERRα vs. ERRγ: Which Receptor Matters More?

An important nuance in SLU-PP-332 pharmacology is the differential contribution of ERR subtypes to different biological outcomes. The 2023 exercise capacity study demonstrated that ERRα activation was critical for the exercise endurance phenotype—when ERRα signaling was blocked, the endurance-enhancing effects of SLU-PP-332 were abolished (Billon et al., 2023). However, the 2024 heart failure study from Circulation found that ERRγ was the primary mediator of cardioprotective effects, using both in vitro and in vivo genetic dependency experiments to demonstrate this specificity (Xu et al., 2024). This tissue-specific receptor dependency is an important consideration for understanding why SLU-PP-332 may produce different benefit profiles in skeletal muscle versus cardiac tissue, and it informs the ongoing development of more selective ERR agonists.

Why Is SLU-PP-332 Called an “Exercise in a Pill”?

The phrase “exercise in a pill” has captured public imagination ever since Nature featured SLU-PP-332 in a 2024 article titled “Why is exercise good for you? Scientists are finding answers in our cells” (Conroy, 2024). But the label is both illuminating and misleading, and understanding why requires examining what exercise actually does at the molecular level and how closely SLU-PP-332 replicates those effects.

What Exercise Does to Your Cells

When you engage in sustained aerobic exercise—running, cycling, swimming—your skeletal muscle cells experience a cascade of metabolic stresses that trigger adaptive responses. ATP is rapidly consumed, AMP levels rise, calcium floods the cytoplasm, and reactive oxygen species increase transiently. These signals converge on master regulatory proteins including AMPK, CaMKII, and ultimately PGC-1α, which then drive the transcription of genes responsible for building new mitochondria, increasing capillary density, converting fast-twitch muscle fibers to fatigue-resistant slow-twitch fibers, and upregulating the enzymatic machinery for fatty acid oxidation. Over weeks and months of repeated exercise bouts, these adaptations accumulate into what we recognize as improved cardiovascular fitness and endurance capacity.

How SLU-PP-332 Shortcuts the Process

SLU-PP-332 essentially enters this cascade at the level of transcriptional regulation, bypassing the upstream mechanical and metabolic stress signals entirely. By directly activating ERRα and recruiting PGC-1α, it instructs muscle cells to execute the same genetic program that exercise would trigger—but without requiring a single step on a treadmill. The 2023 ACS Chemical Biology study demonstrated this convincingly. Mice treated with SLU-PP-332 showed a significant increase in type IIa oxidative muscle fibers and, critically, an ERRα-dependent acute aerobic exercise genetic program was induced even without physical activity. On treadmill tests, treated mice ran approximately 70% farther than untreated controls, a magnitude of endurance improvement that would typically require weeks of progressive training in untreated animals (Billon et al., 2023).

What SLU-PP-332 Cannot Replace

However, calling SLU-PP-332 a complete “exercise replacement” overstates what the compound does. Physical exercise produces benefits that extend far beyond metabolic adaptation in skeletal muscle. Exercise strengthens bones through mechanical loading, improves joint mobility, enhances neuromuscular coordination, releases brain-derived neurotrophic factor (BDNF) for cognitive benefits, modulates immune function, and produces profound psychological effects through endorphin release and social interaction. SLU-PP-332 addresses only the metabolic and mitochondrial components of this vast benefit spectrum. For patient populations who genuinely cannot exercise—the elderly with mobility limitations, individuals recovering from surgery, patients with severe heart failure or neuromuscular diseases—even this partial replication of exercise benefits could be transformative. The compound is best understood as a metabolic exercise mimetic rather than a total exercise substitute.

SLU-PP-332 Benefits: What Preclinical Research Actually Shows

The published preclinical evidence for SLU-PP-332 spans three major peer-reviewed studies conducted between 2023 and 2024, each examining different facets of the compound’s biological activity. It is essential to emphasize that all findings come from mouse models and in vitro cell studies—no human clinical trial data exists for SLU-PP-332 as of 2025. The following benefit categories represent what has been demonstrated in controlled preclinical research environments.

Benefit 1: Enhanced Exercise Endurance

The most striking and widely reported finding is the dramatic improvement in exercise capacity observed in the 2023 study. Mice administered SLU-PP-332 ran approximately 70% farther on treadmill endurance tests compared to vehicle-treated controls. This improvement was accompanied by measurable changes in muscle fiber composition, with treated animals showing significantly increased type IIa oxidative fibers—the same slow-twitch, fatigue-resistant fibers that elite endurance athletes develop through years of training. Mechanistically, the study confirmed that this endurance enhancement was ERRα-dependent, as the effect was abolished when ERRα signaling was genetically disrupted (Billon et al., ACS Chem. Biol., 2023).

Benefit 2: Fat Loss Without Diet or Exercise Changes

The 2024 metabolic syndrome study provided compelling evidence for SLU-PP-332’s fat-reducing effects. In diet-induced obese (DIO) mice—animals fed a high-fat diet to simulate human obesity—28 days of SLU-PP-332 treatment produced approximately 12% body weight reduction. Crucially, this weight loss came entirely from decreased fat mass with no reduction in lean body mass and no changes in food intake or locomotor activity. The compound essentially reprogrammed fuel utilization without suppressing appetite or increasing physical movement. Respiratory exchange ratio (RER) measurements showed that this metabolic shift toward fat oxidation occurred within just two hours of the very first dose, indicating remarkably rapid onset of action. In genetically obese ob/ob mice, the compound also decreased overall adiposity, reduced liver weight, and attenuated hepatic steatosis (fatty liver disease) (Billon et al., J. Pharmacol. Exp. Ther., 2024).

Benefit 3: Improved Glucose Tolerance and Metabolic Flexibility

Beyond fat loss, SLU-PP-332 improved glucose tolerance in diet-induced obese mice, addressing one of the core pathological features of metabolic syndrome and type 2 diabetes. By upregulating PDK4 (pyruvate dehydrogenase kinase 4)—a key enzyme that shifts substrate utilization from glucose to fatty acids—the compound enhanced metabolic flexibility, enabling cells to toggle more efficiently between fuel sources depending on physiological demands. This dual action on both fat metabolism and glucose handling positions SLU-PP-332 as a potential tool for addressing the multi-factorial nature of metabolic syndrome, where insulin resistance, dyslipidemia, and excess adiposity occur simultaneously (Billon et al., 2024).

Benefit 4: Cardioprotection in Heart Failure Models

Perhaps the most clinically significant finding comes from the 2024 Circulation study, which demonstrated that both SLU-PP-332 and its structurally distinct successor SLU-PP-915 provided substantial cardioprotection in a pressure-overload model of heart failure. Treated mice showed significantly improved ejection fraction (a measure of how well the heart pumps blood), ameliorated cardiac fibrosis, and increased survival rates compared to vehicle-treated controls. Metabolomics analysis revealed substantial normalization of fatty acid, lipid, and TCA/oxidative phosphorylation metabolites in the failing heart. Electron microscopy showed that mitochondrial ultrastructure—severely fragmented and damaged in untreated heart failure hearts—was preserved in ERR agonist-treated animals. Remarkably, these cardioprotective effects occurred without affecting cardiac hypertrophy, suggesting that ERR agonism prevents the transition from compensatory hypertrophy to decompensated heart failure rather than preventing hypertrophy itself (Xu et al., Circulation, 2024).

Benefit 5: Mitochondrial Biogenesis and Muscle Fiber Conversion

Running through all of SLU-PP-332’s documented benefits is its fundamental effect on mitochondrial biology. The compound drives the creation of new mitochondria (biogenesis) and improves the oxidative capacity of existing ones. In isolated adult mouse cardiomyocytes, SLU-PP-332 treatment significantly elevated maximal respiratory capacity and increased palmitate-induced oxygen consumption, directly demonstrating enhanced fatty acid oxidation at the cellular level. In skeletal muscle, the conversion of glycolytic fibers to oxidative fibers represents a structural remodeling that underlies the endurance improvements (Billon et al., 2023; Xu et al., 2024).

SLU-PP-332 vs. Other Exercise Mimetics: How Do They Compare?

SLU-PP-332 exists within a growing class of compounds collectively described as exercise mimetics, each targeting different molecular pathways to replicate specific aspects of exercise physiology. Understanding how these compounds differ in mechanism, efficacy, and safety profile is essential for researchers designing studies in this space and for consumers trying to make sense of the often-confusing marketplace of metabolic modulators.

SLU-PP-332 vs. Cardarine (GW501516)

Cardarine and SLU-PP-332 are perhaps the two most frequently compared exercise mimetics. Cardarine activates PPARδ (peroxisome proliferator-activated receptor delta), a nuclear receptor that regulates fatty acid catabolism and energy expenditure in muscle. Both compounds increase endurance and promote fat oxidation, and both are banned by WADA under the same S4 category. However, there is one critical difference that separates them. Cardarine’s clinical development was permanently abandoned by GlaxoSmithKline in 2007 after preclinical studies in rats revealed an increased incidence of tumors across multiple organ systems during long-term, high-dose exposure. While the relevance of these findings to human physiology at lower doses remains debated, the carcinogenicity signal was considered sufficiently concerning to halt all human development. SLU-PP-332, by contrast, has not shown similar carcinogenicity signals in any published preclinical study, though it must be noted that long-term carcinogenicity studies specifically designed to evaluate this endpoint have not been published for SLU-PP-332 either.

SLU-PP-332 vs. SR9009 (Stenabolic)

SR9009 targets Rev-Erbα and Rev-Erbβ, nuclear receptors that modulate circadian rhythm and downstream metabolic processes. While SR9009 demonstrated impressive fat loss and metabolic effects in early mouse studies, subsequent research revealed critically poor oral bioavailability—when administered orally, very little of the compound reaches systemic circulation. This pharmacokinetic limitation has raised questions about whether the metabolic effects observed in studies using intraperitoneal injection would translate to practical oral dosing scenarios. SLU-PP-332 faces similar bioavailability constraints when administered orally in its current formulation, though the next-generation compound SLU-PP-915 was specifically designed to address this limitation (Billon et al., J. Pharmacol. Exp. Ther., 2026).

SLU-PP-332 vs. SLU-PP-915: The Next Generation

SLU-PP-915 is a second-generation pan-ERR agonist developed by the same research group. It is structurally distinct from SLU-PP-332—built on a thiophene scaffold rather than SLU-PP-332’s original chemical framework—and was designed using a structure-based approach leveraging the crystal structure of ERRγ with the known agonist GSK-4716. SLU-PP-915 shows more balanced activity between ERRα and ERRγ (EC50 approximately 450 nM for both) and, importantly, demonstrated oral bioavailability in preclinical models. In the heart failure study, SLU-PP-915 showed even stronger cardioprotective effects than SLU-PP-332, significantly improving ejection fraction, stroke volume, and cardiac output. The development of a structurally distinct second compound that produces the same therapeutic effects was considered particularly important because it provided definitive evidence that the observed benefits were truly ERR-mediated (on-target) rather than artifacts of a single compound’s off-target effects (Hampton et al., 2023; Xu et al., 2024).

SLU-PP-332 Dosage: What Preclinical Studies Used

Establishing a definitive “recommended dosage” for SLU-PP-332 is not possible because no human clinical trials have been conducted and no regulatory body has approved any dose for human use. What follows is a summary of the dosing protocols used in published preclinical research, along with a candid discussion of the anecdotal community practices that have emerged despite the absence of human safety data.

Published Preclinical Dosing Protocols

Several important details emerge from these protocols. First, every published study used intraperitoneal injection, not subcutaneous injection or oral administration. IP injection delivers the compound directly into the abdominal cavity, providing rapid absorption but representing a route of administration that is standard in rodent research yet impractical for human use. Second, the dosing schedule was consistently twice daily, timed to the beginning and midpoint of the light/dark cycle (ZT0 and ZT12), suggesting that the compound’s pharmacokinetics require split dosing to maintain effective plasma concentrations. Third, the vehicle formulation—12% DMSO and 15% Cremophor EL in PBS—was necessary to solubilize SLU-PP-332 for injection, reflecting the compound’s limited aqueous solubility. The stock solution was prepared at 5 mg/mL, stored at −20°C as DMSO stock, diluted with Cremophor before use, and refrigerated at 4°C for no more than five days before final dilution in PBS (Xu et al., 2024).

Allometric Dose Scaling: Why Mouse Doses Cannot Be Directly Applied to Humans

A common and dangerous error in the research chemical community is directly converting mouse mg/kg doses to human doses by simple body weight multiplication. This approach is pharmacologically incorrect. Mice have significantly higher metabolic rates per kilogram of body weight than humans, meaning they clear drugs much faster. The FDA-recommended allometric scaling factor for converting mouse doses to human equivalent doses is division by 12.3. Thus, a 25 mg/kg mouse dose would scale to approximately 2 mg/kg in humans, or roughly 140–160 mg for a 70–80 kg adult. However, this calculation is purely mathematical and does not account for differences in absorption, distribution, metabolism, receptor sensitivity, or toxicity between species. It should not be interpreted as a recommended human dose.

Anecdotal Community Protocols

Despite the absence of human safety data, an underground community of self-experimenters has emerged, sharing dosing protocols on forums and social media. Commonly reported anecdotal doses range from 10 mg to 30 mg daily, typically administered subcutaneously. Some users report splitting doses morning and evening to mirror the twice-daily preclinical protocol. These are entirely unvalidated practices based on personal experimentation rather than controlled clinical investigation, and they carry significant unknown risks.

What Are the Side Effects of SLU-PP-332?

The honest answer to this question is that the side effect profile of SLU-PP-332 in humans is completely unknown. No human clinical trial—not even a Phase I safety study—has been conducted. What we can discuss is the safety data generated from preclinical animal studies and the theoretical concerns that pharmacologists have raised based on the compound’s mechanism of action.

Preclinical Safety Data

Across the published mouse studies, the safety signals have been generally reassuring at the doses tested. In the six-week heart failure study (the longest published treatment duration), mice received SLU-PP-332 at 25 mg/kg intraperitoneally twice daily for 42 consecutive days. The researchers explicitly stated that “no overt toxicity” was observed. Specific safety metrics included no significant changes in clinical chemistry parameters, no adverse effects on food intake or body weight in sham-operated (healthy) animals, no changes in locomotor activity, and preservation of lean body mass during fat loss in the metabolic syndrome study. Additionally, the fat loss observed in obese mice was driven entirely by reduced adiposity rather than muscle wasting, which would have suggested catabolic toxicity (Billon et al., 2024; Xu et al., 2024).

Theoretical Safety Concerns

Despite the favorable preclinical safety profile, several theoretical concerns deserve careful consideration. First, chronically activating metabolic pathways that increase mitochondrial activity and fatty acid oxidation could potentially increase reactive oxygen species (ROS) production, contributing to oxidative stress over long treatment durations. Second, while ERR agonism downregulated cell cycle genes in cardiomyocytes (which was considered beneficial for preventing heart failure progression), the long-term consequences of chronically suppressing cell cycle activity in other tissues are unknown. Third, ERRs are expressed in numerous tissues beyond skeletal muscle and heart—including kidney, liver, and brain—and the effects of chronic pan-ERR activation on these organs have not been comprehensively characterized.

Fourth, there is a pharmacokinetic concern. The vehicle formulation used in animal studies (DMSO and Cremophor EL) is not suitable for human administration due to the known toxicity of Cremophor EL, which has been associated with hypersensitivity reactions, nephrotoxicity, and neurotoxicity in clinical settings. Any future human formulation would require a different delivery vehicle, and the pharmacokinetics and safety profile could change substantially as a result.

Unknown Long-Term Risks

The longest published SLU-PP-332 treatment study lasted six weeks in mice, which corresponds to a relatively modest duration in the context of chronic human therapy. Long-term carcinogenicity studies, reproductive toxicity studies, and chronic organ toxicity assessments have not been published. The experience with Cardarine (GW501516)—which showed favorable short-term metabolic effects but developed carcinogenicity signals in longer-term studies—serves as a cautionary example of why short-term preclinical safety data cannot be extrapolated to predict long-term safety.

Can SLU-PP-332 Treat Heart Failure? What the Circulation Study Revealed

The January 2024 publication in Circulation—one of the world’s most prestigious cardiology journals—represents the most clinically significant study on SLU-PP-332 to date. Led by a multi-institutional team including researchers from Baylor College of Medicine, Washington University, the Salk Institute, and the University of Florida, this paper provided the first direct pharmacological evidence that ERR agonism could be a viable therapeutic strategy for heart failure.

The Heart Failure Problem

Heart failure affects an estimated 6.5 million Americans and 23 million people worldwide, with projections exceeding 8 million U.S. cases by 2030. Despite advances in pharmacotherapy including beta-blockers, ACE inhibitors, ARBs, SGLT2 inhibitors, and sacubitril/valsartan, the five-year survival rate remains approximately 50%—comparable to many cancers. A hallmark of heart failure is progressive metabolic remodeling, wherein the failing heart loses its ability to efficiently use fatty acids as fuel and mitochondrial function deteriorates. This metabolic dysfunction both reflects and accelerates the transition from compensated cardiac stress to decompensated heart failure (Xu et al., 2024).

Study Design and Key Results

The researchers used transaortic constriction (TAC) in mice, a well-established surgical model that creates pressure overload on the left ventricle and progressively induces heart failure over four to six weeks. Both SLU-PP-332 and SLU-PP-915 were administered starting one day after surgery at 25 mg/kg IP twice daily. The results were striking across multiple endpoints. Vehicle-treated mice showed progressive decline in ejection fraction from approximately 68% to 34% over six weeks. Mice treated with SLU-PP-332 maintained significantly higher ejection fraction, and SLU-PP-915 showed even stronger improvement, reaching significance as early as two weeks post-surgery. Both compounds reduced cardiac fibrosis, as demonstrated by Masson trichrome staining, and decreased expression of cardiac stress markers (Nppa and Nppb). Most importantly, ERR agonist-treated mice showed significantly improved survival compared to vehicle-treated controls.

The Metabolic Rescue Mechanism

Comprehensive metabolomics analysis of heart tissue revealed the mechanism underlying these cardioprotective effects. Six-week TAC induced dramatic changes in cardiac metabolite profiles, with 112 lipid and fatty acid metabolites decreased in failing hearts. In ERR agonist-treated animals, only 5 lipid/FA metabolites were decreased—representing a near-complete normalization of lipid metabolism. Similarly, 46% of TCA cycle and oxidative phosphorylation metabolites were disrupted by TAC, but only 8% were affected in the treatment group. This metabolic rescue was accompanied by preserved mitochondrial ultrastructure on electron microscopy—treated hearts showed intact cristae and organized mitochondrial architecture, in stark contrast to the fragmented, disorganized mitochondria characteristic of untreated failing hearts (Xu et al., 2024).

Is SLU-PP-332 Banned? WADA Status and Legal Considerations

The regulatory and legal status of SLU-PP-332 depends entirely on the context in which the compound is being considered. For competitive athletes, research institutions, and individual consumers, the rules are very different.

WADA Prohibited List Status

SLU-PP-332 is explicitly listed on the World Anti-Doping Agency (WADA) Prohibited List under category S4: Hormone and Metabolic Modulators. This prohibition applies at all times, both in-competition and out-of-competition, meaning that any athlete subject to WADA-governed drug testing who tests positive for SLU-PP-332 or its metabolites would face a doping violation and potential multi-year ban from competition. The prohibition reflects WADA’s assessment that the compound’s demonstrated ability to enhance endurance and metabolic performance represents an unacceptable performance-enhancing advantage in sport.

Anti-doping laboratories have already developed validated detection methods for both SLU-PP-332 and SLU-PP-915. A 2026 study by Möller, Krug, and Thevis in Rapid Communications in Mass Spectrometry characterized the in vitro metabolism of both compounds and identified specific metabolite signatures that can be detected in biological samples. A separate study by Avliyakulov, Sobolevsky, and Ahrens (2026) in Drug Testing and Analysis further validated these detection methods for doping control purposes.

United States Legal Status

In the United States, SLU-PP-332 is not a controlled substance under the Controlled Substances Act. It is not scheduled by the DEA and is not prohibited from sale or possession for research purposes. It occupies the legal category of a “research chemical”—a compound that can be legally purchased, possessed, and used strictly for laboratory and experimental purposes but is not approved for human consumption. This distinction is critical. The compound carries no FDA approval, has no recognized medical indication, and cannot be legally marketed as a dietary supplement, food additive, or therapeutic drug. Legitimate suppliers label SLU-PP-332 as “For Research Purposes Only” and “Not for Human Consumption,” and any supplier marketing it for human use would be operating in violation of federal regulations.

International Regulatory Variation

Regulatory frameworks for research chemicals vary significantly by country. Some jurisdictions have enacted broader prohibitions on novel psychoactive and pharmacologically active substances, which could encompass compounds like SLU-PP-332 even outside the context of competitive athletics. Researchers and consumers should verify the specific regulations in their jurisdiction before acquiring this compound. The rapidly evolving regulatory landscape around exercise mimetics and metabolic modulators means that the legal status could change with relatively short notice.

Buying SLU-PP-332 for Research: What to Look For

For researchers conducting legitimate preclinical studies, sourcing high-quality SLU-PP-332 is essential for generating reproducible and meaningful data. The research chemical market varies enormously in quality, purity, and reliability, and the consequences of using contaminated or mislabeled compounds extend beyond wasted experiments to potentially misleading scientific conclusions.

Certificate of Analysis (COA) Requirements

The single most important document when evaluating any research chemical supplier is the Certificate of Analysis. A legitimate COA should include HPLC (high-performance liquid chromatography) purity data confirming greater than 98% purity, mass spectrometry data confirming molecular identity, batch-specific testing results rather than generic documentation, and ideally third-party analytical verification from an independent laboratory. If a supplier cannot provide a current, batch-specific COA upon request, this represents a significant red flag regardless of pricing or marketing claims.

Supplier Evaluation Checklist

Beyond the COA, several additional factors distinguish reliable research chemical suppliers from questionable ones. Look for US-based operations with transparent business registration, consistent inventory availability rather than dropshipping from overseas manufacturers, responsive customer support with technical knowledge of the compounds they sell, proper labeling stating “For Research Purposes Only” and “Not for Human Consumption,” and clear terms of service that restrict sales to legitimate research applications. Transparent pricing is also important—dramatically low prices often indicate either diluted product, lower purity, or contamination with synthesis byproducts.

Storage and Handling

Proper storage is essential for maintaining compound integrity. SLU-PP-332 should be stored in a cool, dark, and dry environment. For long-term storage, refrigeration (2–8°C) or freezing (−20°C) is recommended. Once reconstituted in DMSO or other solvent systems, the solution should be aliquoted to minimize freeze-thaw cycles and used within the timeframes established in the published literature—typically within five days when stored at 4°C in the DMSO/Cremophor vehicle (Xu et al., 2024). Standard laboratory personal protective equipment including gloves and safety glasses should be worn when handling the compound.

Key Takeaways: SLU-PP-332 in 2025

SLU-PP-332 represents one of the most scientifically compelling exercise mimetic compounds to emerge from academic research in the past decade. Its ability to activate estrogen-related receptors and trigger the genetic programs associated with aerobic exercise has produced remarkable preclinical results across three distinct therapeutic areas: endurance enhancement, metabolic syndrome improvement, and heart failure cardioprotection. The publication of the heart failure data in Circulation—a top-tier journal with an impact factor exceeding 35—lends particular credibility to the compound’s therapeutic potential and has catalyzed significant interest from both the scientific community and the broader public.

However, the current reality of SLU-PP-332 must be understood within its proper context. Every piece of efficacy data comes from mouse models and cell lines. No human clinical trial has been conducted. The compound is not FDA-approved for any indication. Its safety profile in humans is entirely unknown, and the longest published treatment duration in animals is just six weeks. The experience with Cardarine—a compound with similarly impressive short-term preclinical results that was ultimately abandoned due to carcinogenicity concerns—provides an important reminder that preclinical promise does not guarantee clinical success.

For the research community, SLU-PP-332 and its successor SLU-PP-915 represent valuable pharmacological tools for studying ERR biology, mitochondrial metabolism, and the molecular mechanisms of exercise adaptation. For patient populations with limited exercise capacity—including the elderly, post-surgical patients, and individuals with severe heart failure—the concept of pharmacological exercise mimicry holds genuine therapeutic potential that justifies continued investigation. For healthy individuals seeking performance enhancement, the risk-benefit calculation of using an unvalidated preclinical compound without human safety data is fundamentally different and demands extreme caution.

The future of this field is already taking shape. SLU-PP-915’s demonstrated oral bioavailability addresses one of SLU-PP-332’s key pharmacokinetic limitations. Anti-doping detection methods are being developed in anticipation of athletic misuse. And the broader scientific community continues to explore ERR agonism as a therapeutic strategy across metabolic disease, neurodegeneration, and aging. Whether SLU-PP-332 itself or a descendant compound eventually enters human clinical trials, the foundational science it has generated has permanently expanded our understanding of how cellular metabolism can be pharmacologically reprogrammed to mimic the benefits of physical exercise.